Doctors at the Urology Group are pioneering the use of artificial intelligence to enhance prostate cancer treatment, offering ...

Statistics show a clear spike in eight cancers in younger people, but that has brought a debate over whether many cases ever ...

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Most of the time, diagnosis happens through ...

The assay detects aggressive prostate tumors in men on active surveillance for low-risk cancer, potentially helping them ...

Telix Pharmaceuticals ( ($AU:TLX) ) has provided an announcement. Telix Pharmaceuticals has announced the dosing of the first patient in Part 2 of ...

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patienthas been dosed in Part 2 ...

The treatment is suitable for men whose cancer has not spread outside of the prostate gland or has spread to the area just outside the gland.

A groundbreaking trial for a prostate cancer treatment with fewer side effects has launched in the UK. Backed by the ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Experts at SICP 2025 outline how molecular mechanisms and bedside assessments can guide personalised treatment for ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...